These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 7313673)

  • 1. [Pharmacokinetics of propranolol, the beta-adrenergic receptor blocking agents (author's transl)].
    Lou YQ
    Sheng Li Ke Xue Jin Zhan; 1981 Feb; 12(2):167-70. PubMed ID: 7313673
    [No Abstract]   [Full Text] [Related]  

  • 2. [Effect of temperature on the kinetics of propranolol, theophylline, phenytoin and digoxin in rats (author's transl)].
    Albin H; Vincon G; Ploux D; Dangoumau J
    J Pharmacol; 1981; 12(3):229-38. PubMed ID: 7289622
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Interaction of phenobarbital with propranolol in the dog. 3. Beta blockade.
    Bai SA; Abramson FP
    J Pharmacol Exp Ther; 1983 Jan; 224(1):62-7. PubMed ID: 6129320
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The disposition of propranolol. 3. Decreased half-life and volume of distribution as a result of plasma binding in man, monkey, dog and rat.
    Evans GH; Nies AS; Shand DG
    J Pharmacol Exp Ther; 1973 Jul; 186(1):114-22. PubMed ID: 4198771
    [No Abstract]   [Full Text] [Related]  

  • 5. [Effect of a beta-adrenergic blocking agent on erythropoietin production in the mouse (author's transl)].
    Guidi EE; Scaro JL; Carrera MA
    Rev Esp Fisiol; 1976 Jun; 32(2):149-52. PubMed ID: 935624
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Kinetics of distribution of di-propranolol in various organs and discrete brain areas of the rat.
    Bianchetti G; Elghozi JL; Gomeni R; Meyer P; Morselli PL
    J Pharmacol Exp Ther; 1980 Sep; 214(3):682-7. PubMed ID: 7400970
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The disposition of propranolol. 8. General implications of the effects of liver blood flow on elimination from the perfused rat liver.
    Branch RA; Nies AS; Shand DG
    Drug Metab Dispos; 1973; 1(5):687-90. PubMed ID: 4149707
    [No Abstract]   [Full Text] [Related]  

  • 8. [Physiological disposition of changrolin (author's transl)].
    Zeng YL; Yi QC; Gu HM; Qu ZX; Xu GY
    Zhongguo Yao Li Xue Bao; 1981 Sep; 2(3):177-81. PubMed ID: 6462008
    [No Abstract]   [Full Text] [Related]  

  • 9. [Propranolol pharmacokinetics in elderly persons].
    Halawa B; Mazurek W
    Pol Tyg Lek; 1983 Oct; 38(44):1363-6. PubMed ID: 6674960
    [No Abstract]   [Full Text] [Related]  

  • 10. [Determination of nevadensin in specimens and its pharmacokinetic (author's transl)].
    Han GZ; Su CY; Zhang Y
    Zhongguo Yao Li Xue Bao; 1981 Sep; 2(3):182-5. PubMed ID: 6462009
    [No Abstract]   [Full Text] [Related]  

  • 11. No enhanced elimination of propranolol in patients with hyperthyroidism.
    Ishizaki T; Masuno M; Tawara K
    Res Commun Chem Pathol Pharmacol; 1980 Sep; 29(3):473-85. PubMed ID: 7423023
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of chlorpromazine on the disposition and beta-adrenergic blocking activity of propranolol in the dog.
    Bai SA; Abramson FP
    J Pharmacokinet Biopharm; 1984 Jun; 12(3):333-49. PubMed ID: 6502474
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Influence of nephrectomy on the antihypertensive effects of propranolol in the dog (author's transl)].
    Montastruc JL; Gaillard-Plaza G; Thomas J; Montastruc P
    J Pharmacol; 1981; 12(4):465-70. PubMed ID: 7321575
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Analysis of hepatic metabolism affecting pharmacokinetics of propranolol in humans.
    Kiriyama A; Honbo A; Iga K
    Int J Pharm; 2008 Feb; 349(1-2):53-60. PubMed ID: 17765415
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Comparative studies on the absorption, distribution and excretion of 14C-gossypol in four species of animals (author's transl)].
    Tang XC; Zhu MK; Shi QX
    Yao Xue Xue Bao; 1980 Apr; 15(4):212-7. PubMed ID: 6779501
    [No Abstract]   [Full Text] [Related]  

  • 16. [Clearance concept applied to pharmacokinetics: 1. Application for the study of tolamolol (beta-blocking agent) in healthy volunteers (author's transl)].
    Balant L; Faulkner JK; Tozer TN
    Nephrologie; 1980; 1(4):172-6. PubMed ID: 6895407
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Likely explanation for longer duration of pharmacological (antianginal) effects of propranolol in relation to its short half-life.
    Ishizaki T
    Res Commun Chem Pathol Pharmacol; 1980 Feb; 27(2):223-39. PubMed ID: 7367746
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Stereoselective pharmacokinetics of oxprenolol, propranolol, and verapamil: species differences and influence of endotoxin.
    Laethem ME; Belpaire FM; Wijnant P; Bogaert MG
    Chirality; 1995; 7(8):616-22. PubMed ID: 8593255
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The application of clearance concepts to propranolol disposition in man.
    Wilkinson GR
    Drug Metab Rev; 1979; 10(1):107-23. PubMed ID: 393480
    [No Abstract]   [Full Text] [Related]  

  • 20. [Organically bound tritium].
    Zhuravlev VF
    Med Radiol (Mosk); 1981 Jun; 26(6):67-71. PubMed ID: 7022086
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.